- Biopharma M&A maintains strength even as large deals waneBiopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: meg…Endpoints · 2mo ago↗ source
- Amgen expands crackdown on what it says is misuse of 340B programAmgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud…Endpoints · 2mo ago↗ source
- <![CDATA[FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer]]><![CDATA[The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.]]>